Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Agamemnon A. Epenetos"'
Publikováno v:
Journal of Clinical Oncology. 40:96-96
96 Background: The tumor suppressor gene TP53 is one of the most frequently deleted or mutated genes in gastrointestinal cancers. Normal p53 regulates several important proteins that control cell cycle, cell death, DNA damage/repair, stemness, differ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4569ffc06a858320eb21519036c4dc9b
https://doi.org/10.1200/jco.2022.40.4_suppl.096
https://doi.org/10.1200/jco.2022.40.4_suppl.096
Autor:
Konstantinos Kapnisis, Agamemnon A. Epenetos, Christina Kousparou, Marianna Prokopi, Andreas S. Anayiotos, Mahendra Deonarain, Costas Pitsillides
Publikováno v:
Journal of Clinical Oncology. 38:e17601-e17601
Presented in American Society of Clinical Oncology Annual Meeting, 2020 Notch signalling is implicated in tumorigenesis prompting scientists to research and develop anti-Notch therapeutics. Drugging the Notch pathway has been a challenge due to sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219c1de6fb2dbff33d2bd149f1e17867
https://doi.org/10.1200/jco.2020.38.15_suppl.e17601
https://doi.org/10.1200/jco.2020.38.15_suppl.e17601
Publikováno v:
Cancer Therapy with Radiolabeled Antibodies ISBN: 9781351070409
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::044482fa4e9421d4794848ed0045d782
https://doi.org/10.1201/9781351070409-12
https://doi.org/10.1201/9781351070409-12
Publikováno v:
Delivery Strategies for Antisense Oligonucleotide Therapeutics ISBN: 9781315150901
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d45b767a353c486d7165af2d895791c5
https://doi.org/10.1201/9781315150901-18
https://doi.org/10.1201/9781315150901-18
Autor:
Graham S. Ogg, Brian Gazzard, Mark T. Nelson, Justin Stebbing, Frances Gotch, Agamemnon A. Epenetos, Steve Patterson, Philip Savage, Mark Bower
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b66e4e0af32a9f3d389019a05f8e036
https://doi.org/10.1097/00002030-200410210-00020
https://doi.org/10.1097/00002030-200410210-00020
Autor:
Nicholas R. Lemoine, Aled Clayton, Andrew J. McMichael, Thomas Lawson, Pam Cowburn, Stephen Man, Philip Savage, Graham S. Ogg, Agamemnon A. Epenetos
A number of experimental antibody mediated cancer therapies aim to redirect cytotoxic T cells (CTLs) of non-tumour specificity to cancer cells. It has been previously demonstrated that cancer cells targeted with recombinant HLA-class I/viral peptide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bdda8db1295554f735f827104cc8fae
https://doi.org/10.1002/ijc.10219
https://doi.org/10.1002/ijc.10219
Autor:
Mahendra Deonarain, Aleksandra Filipovic, Christina Kousparou, Costas Pitsillides, Andreas S. Anayiotos, Agamemnon A. Epenetos, Konstantinos Kapnisis, Marianna Prokopi
Presented in ASCO Annual Meeting, 2016, 3 June — 7 June, Chicago, United States of America Background: The Notch pathway has been associated with cancer and is implicated in tumorigenesis and regulation of cell fate. This pathway is an attractive t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77f272737d0d1c3498e268fb0baec567
https://hdl.handle.net/20.500.14279/16135
https://hdl.handle.net/20.500.14279/16135
Autor:
Christina Kousparou, Marianna Proklopi, Andreas S. Anayiotos, Agamemnon A. Epenetos, Konstantinos Kapnisis, Costas Pitsillides, Aleksandra Filipovic
Presented in ASCO Annual Meeting, 2016, 3 June — 7 June, Chicago, United States of America Background: Current cancer therapies are partially effective in tumor eradication, due to intrinsic drug resistance as well as failure of therapeutic agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9472ffa652148c5de56aae2532a9e2ee
https://hdl.handle.net/20.500.14279/16139
https://hdl.handle.net/20.500.14279/16139
Autor:
Stuart M. Haslam, Kerry A. Chester, Bijal Vyas, Kevin Canis, Mahendra Deonarain, Anne Dell, Antony Constantinou, Agamemnon Antoniou Epenetos, Chen Chen
Publikováno v:
Bioconjugate Chemistry. 23:1524-1533
The potential for protein-engineered biotherapeutics is enormous, but pharmacokinetic modulation is a major challenge. Manipulating pharmacokinetics, biodistribution, and bioavailability of small peptide/protein units such as antibody fragments is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b835a1e8af792d1daadad97086824600
https://doi.org/10.1021/bc200624a
https://doi.org/10.1021/bc200624a
Autor:
M Wright, Mahendra Deonarain, Kerry A. Chester, Antony Constantinou, Agamemnon Antoniou Epenetos, Dale Howard Hreczuk-Hirst, Sanjay Jain
Publikováno v:
Bioconjugate Chemistry. 20:924-931
Protein pharmacokinetic modulation is becoming an important tool in the development of biotherapeutics. Proteins can be chemically or recombinantly modified to alter their half-lives and bioavailability to suit particular applications as well as impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf9625de5e07d0baf2d1ec3360ed2b0f
https://doi.org/10.1021/bc8005122
https://doi.org/10.1021/bc8005122